Defilade Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Defilade Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.1M	Buy	+1,674,999	New	+$4.1M	0.41%	38

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Defilade Capital Management's BDTX Position: Q2 2026 in Review

Defilade Capital Management opened a new position in Black Diamond Therapeutics (BDTX) in Q2 2026: 1,674,999 shares worth $3.1M. The stake represents 0.41% of the portfolio and ranks #38 among its holdings.

94 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

Defilade Capital Management held 1,674,999 shares of Black Diamond Therapeutics worth $3.1M as of Q2 2026.
Black Diamond Therapeutics was a new Defilade Capital Management position in Q2 2026.
Black Diamond Therapeutics made up 0.41% of Defilade Capital Management's portfolio in Q2 2026, its #38 holding.
94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.